Tech Company Financing Transactions

Sienna Biopharmaceuticals Funding Round

On 4/26/2017, Sienna Biopharmaceuticals landed $40 million in Series B investment from Arch Venture Partners, Altitude Life Science Ventures and Clough Capital Partners.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

30699 Russell Ranch Rd. 140
Westlake Village, CA 91362
USA

Phone

818-629-2256

Website

www.siennabio.com

Email Address

Not Recorded

Overview

Sienna Biopharmaceuticals (NASDAQ: SNNA) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians' practice of medicine.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Frederick Beddingfield

        

Chief Financial Officer

John Smither

        

Chief Medical Officer

Paul Lizzul

        

Chief Scientific Officer

Silvio Traversa

        

Vice President

Debra Condino

        

VP - Bus. Development

Todd Harris

        

VP - Bus. Development

Caroline Hove

        

VP - General Counsel

Timothy Andrews

        

VP - Operations

Majed Kheir

        

VP - Regulatory Affairs

Ryan Irvine

        

VP - Regulatory Affairs

Diane Stroehmann

        

Browse more venture capital transactions:

Prev: 4/26/2017: Token venture capital transaction
Next: 4/26/2017: Dave venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary